BWIN · The Baldwin Insurance Group, Inc. · Stock research

Current Thesis

The August frame was a post-print re-rating running ahead of an unconfirmed deal. Since then the deal leg has produced nothing dated. The strategic-review report (Insurance Insider, 2026-06-18, naming Ardea as adviser) is now nine weeks old with no 8-K, no named bidder, no exclusivity and no company comment. Price has gone sideways at the top of the move: $31.51 on 2026-08-14, $31.90 on 2026-08-21, against a 52-week high of $34.11. What an investor buys here is the second leg — a signed take-private at a price starting with a 3, underwritten by $116.7M of Q2 adjusted EBITDA and $46.4M of adjusted free cash flow — at a price that already sits on the sell-side consensus of $32.22 across 10 analysts (stockanalysis.com, 2026-08-21) and above the $28.50–30.00 per share band third-party deal work modelled in June at a 7.7% year-one free-cash-flow yield.

The narrative is maturing. The attention leg is dated and finished expanding: the 19% single-session move on 2026-06-22, JPMorgan's upgrade to Overweight the same day, then a six-week ladder of target raises — BMO $25 (2026-06-23), KBW $31 (2026-07-08), Wells Fargo $27 (2026-07-09) then $28 (2026-08-03), JPMorgan $30 (2026-07-13), UBS $37 (2026-08-03). Nothing has printed since 2026-08-03. The structure is intact and price is 6.5% off its high, so this is not a broken narrative; but the new-headline flow has stopped and price is at consensus. It flips to saturated if the process lapses into the Q3 print without confirmation.

Bullish and bearish views on The Baldwin Insurance Group, Inc.

The model's bull view on The Baldwin Insurance Group, Inc. (BWIN), in brief: Q3 guide was raised above the street at the Q2 print. The bear view: Organic growth printed 2% in both Q1 and Q2 2026 against a mid-single-digit full-year assumption, with a 240 bps drag from rate and exposure and 150 bps from a procedural accounting change; legacy IAS organic was -2% on roughly $8M of annualized integration attrition. Both cases follow in full.

Bull Case

• Q3 guide was raised above the street at the Q2 print. Guidance issued 2026-07-30 for Q3 2026: revenue $485–495M and adjusted EPS $0.42–0.46 against a consensus EPS estimate of $0.41 (MarketBeat guidance alert, 2026-07-30).
• Q2 revenue cleared the company's own guide. $492.9M, +30% YoY, versus a $485–490M guide; H1 revenue $1.0B, +29% (results 2026-07-30).
• Margin and cash conversion improved together. Q2 adjusted EBITDA $116.7M, +37% YoY, margin 23.7% versus 22.6% a year earlier; adjusted free cash flow $46.4M, +437% YoY; operating cash flow $45.6M.
• The company bought its own stock through the drawdown. $126.8M of repurchases in H1 2026, with $184.5M of cash and $259.4M of revolver capacity at 2026-06-30 — capital returned rather than equity issued into the rumor.
• Consensus has migrated up to price, not down to it. The 10-analyst average of $32.22 on 2026-08-21 compares with the 7-analyst $30.43 average quoted in mid-August; the high end of the range is UBS at $37 (2026-08-03).
• The Anthropic deployment (2026-05-04) — Baldwin named first enterprise customer of Anthropic's JV with Blackstone, Goldman Sachs, Hellman & Friedman, General Atlantic and Sequoia — feeds the 3B30 target of $3B revenue and 30% margins by 2029 and still carries no quantified P&L line.

Bear Case

• Organic growth printed 2% in both Q1 and Q2 2026 against a mid-single-digit full-year assumption, with a 240 bps drag from rate and exposure and 150 bps from a procedural accounting change; legacy IAS organic was -2% on roughly $8M of annualized integration attrition.
• Still GAAP loss-making. Q2 net loss $56.0M, or -$0.42 per share; H1 net loss $57.9M. The equity case runs on adjusted EBITDA, adjusted EPS ($0.48 in Q2, +14%) and synergy delivery.
• Price is through the modelled takeout band. A merger agreement disclosing consideration inside $28.50–30.00 would be a down move from the 2026-08-21 close of $31.90.
• Buyer constraints are the same features that made the LBO plausible. Third-party analysis cites leverage near 4.3x plus roughly $220M of contingent earnouts.
• The premium has no scheduled resolution. Between 2026-06-18 and 2026-08-21 the only company-sourced events were the Q2 results and guidance; the process itself has produced zero disclosure.

Setup & Price Structure

• Reference close $31.90 on 2026-08-21; 52-week high $34.11, so 6.5% below it. Three-month price change of +62.3%. RSI(14) at 64.2 — extended but not at the 70 line.
• Weekly closes have compressed at the highs: $27.25 (2026-07-17) pre-print, $31.51 (2026-08-14), $31.90 (2026-08-21). The print gap zone runs roughly $27–31.5, which makes $28–30 the give-back shelf and coincides with the modelled deal band.
• Pre-rumor support is a zone, not a print: vendor price histories disagree around the 2026-06-22 gap, so treat $23–24 as the pre-rumor shelf.
• Crowding observables (stated, not judged): price at 99% of the 10-analyst consensus target; six sell-side target raises between 2026-06-22 and 2026-08-03 and none in the 18 sessions since; retail-facing coverage clustered at the entry of the move (Benzinga "big stocks moving higher", 2026-06-22; Seeking Alpha "Go-Private Rumors Appear Credible"); no earnings date inside 30 days; float shrinking via $126.8M of H1 buybacks rather than expanding via issuance.

Catalyst Calendar (next 30 days)

• 2026-08-23 → 2026-09-22: no company-confirmed event. No results date, no shareholder meeting, no scheduled guidance update falls inside the window.
• ~2026-10-28 (est.), outside the window: Q3 2026 results, testing the $485–495M revenue guide, the $0.42–0.46 adjusted EPS guide and the $2.01–2.05B full-year revenue guide. The date is inferred from the 2026-07-30 Q2 cadence and is not company-confirmed.

Elapsed catalysts

• Unscheduled, any session: an 8-K confirming or denying the strategic process reported 2026-06-18. This is the only event that can resolve the premium and it carries no date. (passed 69d ago)

What Would Change Our Mind

The structure that matters is the post-print shelf, and the clock that matters is the process. Two things break the read. First, the give-back: a weekly close below $28 puts price back under the $28.50–30.00 band third-party deal work modelled and inside the pre-Q2 range, which would say the market has stopped paying for the deal leg. Second, the lapse: the estimated late-October Q3 print arriving with no 8-K, no named bidder and no exclusivity disclosed, with the company still declining comment — at which point the premium is being carried on a single unconfirmed June report and the label moves to saturated. On the other side, a merger agreement disclosing consideration above $31.90, or a Q3 print showing organic above 4% with the full-year guide intact, would move the case from speculation-driven to earnings-driven and re-open the upside path toward the $37 high target.

Correlation Notes

• Sector beta runs with the listed P&C brokers — MMC, AON, AJG, BRO, RYAN. The 240 bps rate-and-exposure headwind cited on 2026-07-30 is a soft-market condition felt across the group, so an organic miss here is unlikely to be idiosyncratic.
• The take-private leg correlates to credit, not to insurance pricing. A financial buyer levering an issuer already near 4.3x is sensitive to high-yield spreads; a spread-widening episode compresses the deal case and the public equity at the same time.
• The Anthropic/3B30 leg has no tradable correlation yet — it is a 2029 target with no disclosed revenue or cost line, so it does not move with enterprise-AI sentiment in any measurable way.
• Beyond the sector, the name trades on a single unscheduled headline. Index-level moves matter less to it than one trade-press story does.